89
Participants
Start Date
February 7, 2019
Primary Completion Date
May 19, 2022
Study Completion Date
May 19, 2022
Regorafenib and Irinotecan
Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) combined with regorafenib (160 mg daily on D2-8 and D16-22 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
Irinotecan
Irinotecan (180 mg/m² on D1 and D15 of a 4-week cycle) administered until progression of disease or unacceptable toxicity
Centre Georges François Leclerc, Dijon
Institut du Cancer Montpellier, Montpellier
Institut Jean Godinot, Reims
CHU Nancy - Hôpital Brabois, Vandœuvre-lès-Nancy
Hopital Europeen Georges Pompidou, Paris
CHU de Poitiers, Poitiers
Institut de Cancérologie de l'Ouest-Paul Papin, Angers
Hôpital Morvan, Brest
Clinique de Flandre, Coudekerque-Branche
Hôpital Franco-Britannique, Levallois-Perret
Hopital Claude Huriez - CHU Lille, Lille
CHU Dupuytren, Limoges
Centre Léon Bérard, Lyon
Hopital de la Timone, Marseille
Institut Paoli Calmette, Marseille
Centre de Cancérologie du Grand Montpellier, Montpellier
GH Diaconesses Croix Saint-Simon, Paris
CH Saint Jean, Perpignan
CH Annecy Genevois, Pringy
Hopital Robert Debre, Reims
Hopital Charles Nicolle, Rouen
CHP Saint Grégoire, Saint-Grégoire
Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain
CH Saint Malo, St-Malo
Centre Paul Strass, Strasbourg
CHRU Tours, Tours
Centre Antoine Lacassagne, Nice
Collaborators (1)
Bayer
INDUSTRY
UNICANCER
OTHER